Delving into the Latest Updates on LP-97 with Synapse

Overview

Basic Info

Drug Type

Chemical drugs

Synonyms

Target

gp41

Mechanism

gp41 inhibitors(Transmembrane glycoprotein gp41 inhibitors)

Therapeutic Areas

Immune System DiseasesInfectious DiseasesUrogenital Diseases

Active Indication

HIV Infections

Inactive Indication-

Originator Organization

Institute of Pathogen Biology Chinese Academy of Medical Sciences

Active Organization

Institute of Pathogen Biology Chinese Academy of Medical Sciences

Inactive Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

Two HIV fusion-inhibitory lipopeptides (LP-97 and LP-98) were designed with highly potent, long-acting antiviral activity. Monotherapy using a low dose of LP-98 sharply reduced viral loads and maintained long-term viral suppression in 21 SHIV_SF162P3-infected rhesus macaques. We found that five treated monkeys achieved potential posttreatment control (PTC) efficacy and had lower viral DNA in deep lymph nodes, whereas monkeys with a stable viral rebound had higher viral DNA in superficial lymph nodes. The tissues of PTC monkeys exhibited significantly decreased quantitative viral outgrowth and fewer PD-1⁺ central memory CD4⁺ T cells, and CD8⁺ T cells contributed to virologic control efficacy. Moreover, LP-98 administrated as a pre-exposure prophylaxis (PrEP) provided complete protection against SHIV_SF162P3 and SIVmac239 infections in 51 monkeys via intrarectal, intravaginal, or intravenous challenge. In conclusion, our lipopeptides exhibit high potential as an efficient HIV treatment or prevention strategy.

100 Deals associated with LP-97

Login to view more data